Silence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from Brokerages

Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $40.67.

SLN has been the topic of a number of analyst reports. Chardan Capital reaffirmed a "buy" rating and set a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. BMO Capital Markets reduced their price objective on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. Morgan Stanley lowered their target price on shares of Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. The Goldman Sachs Group reduced their price target on Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating on the stock in a research note on Tuesday, March 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Eventide Asset Management LLC bought a new stake in Silence Therapeutics in the third quarter valued at about $11,635,000. Parkman Healthcare Partners LLC lifted its holdings in Silence Therapeutics by 71.8% in the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company's stock worth $9,051,000 after acquiring an additional 208,029 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in Silence Therapeutics by 219.3% in the third quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company's stock valued at $8,505,000 after acquiring an additional 321,300 shares during the period. Janus Henderson Group PLC grew its stake in Silence Therapeutics by 32.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company's stock worth $19,798,000 after buying an additional 268,250 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Silence Therapeutics during the third quarter worth about $207,000. 98.73% of the stock is currently owned by institutional investors.

Remove Ads

Silence Therapeutics Trading Up 11.1 %

Shares of NASDAQ:SLN traded up $0.37 during trading on Monday, hitting $3.69. 177,323 shares of the stock were exchanged, compared to its average volume of 276,869. The company has a market cap of $110.44 million, a PE ratio of -2.35 and a beta of 1.08. The company has a fifty day moving average price of $4.70 and a two-hundred day moving average price of $10.07. Silence Therapeutics has a 12-month low of $3.24 and a 12-month high of $24.38.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.